Cambridge Healthtech Instituteの第15回年次会議
Advanced Diagnostics for Infectious Disease
2023年8月22 - 23日、EDT（米国東部標準時）
Scientific Advisory Board
Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children’s Hospital Los Angeles;
Associate Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California
Erin H. Graf, PhD, D(ABMM), Associate Professor of Laboratory Medicine and Pathology, Co-Director, Microbiology Laboratory,
Mayo Clinic Arizona
Nathan Ledeboer, PhD, Professor and Vice Chair, Pathology and Medical Director, Medical College of Wisconsin
Robin M. Patel, MD, D(ABMM), FIDSA, FACP, F(AAM), FRCPC,
Elizabeth P. and Robert E. Allen Professor of Individualized Medicine; Director, Infectious Diseases Research Laboratory,
Professor of Medicine and Microbiology, Co-Director, Bacteriology Laboratory; Vice Chair of Education,
Department of Laboratory Medicine and Pathology, Mayo Clinic
PLENARY SESSION Co-Organized by PMC
Policy and Practice Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care
Many oncology patients who are eligible to receive high-value personalized treatments do not. Despite a lengthy history of targeted treatment availability in advanced non-small cell lung cancer (aNSCLC), a recent study found that 644 of every 1,000 newly diagnosed aNSCLC patients (64.4%) did not receive a personalized treatment due to clinical practice gaps in the delivery of precision oncology.
- What are the clinical practice and policy challenges related to diagnostic testing and the delivery of appropriate targeted therapies leading to a failure of patients to receive precision oncology strategies?
- What impact does each clinical practice gap have on the population-level delivery of precision oncology?
- How can we optimize biomarker testing and treatment decision-making to help best address clinical practice gaps?
- What policies and practices can help assure optimal and equitable delivery of appropriate high-value personalized medicines?
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own12:30 pm
MULTIPLEX PCR PANELS FOR INFECTIOUS DISEASE TESTING
Robin M. Patel, MD, D(ABMM), FIDSA, FACP, F(AAM), FRCPC, Elizabeth P. and Robert E. Allen Professor of Individualized Medicine; Director, Infectious Diseases Research Laboratory; Professor of Medicine and Microbiology, Co-Director, Bacteriology Laboratory; Vice Chair of Education, Department of Laboratory Medicine and Pathology, Mayo Clinic
Rapid Syndromic Testing for Pneumonia: Current Landscape and Future Directions
Kimberly Hanson, MD, MHS, Director, Transplant Infectious Diseases and Immunocompromised Host Service; Director, Medical Microbiology Fellowship Program, Section Head, Clinical Microbiology, University of Utah, ARUP Laboratories
This session will provide an overview of the current molecular diagnostic landscape for pneumonia, review recent studies assessing the impact of rapid diagnostics, and discuss unmet research needs in pursuit of personalized interventions for lower respiratory tract infection.
Comparison of the BioFire Joint Infection Panel to 16S Ribosomal RNA Gene-Based Targeted Metagenomic Sequencing for Testing Synovial Fluid from Patients with Knee Arthroplasty Failure
The diagnosis of periprosthetic joint infection (PJI) is challenging, often requiring multiple diagnostic techniques. The diagnostic performance of the Investigational Use Only BioFire Joint Infection (JI) Panel was compared to 16S rRNA gene-based targeted metagenomic sequencing applied to PJI synovial fluid. While JI Panel sensitivity was excellent for on-panel microorganisms, overall sensitivity was low due to the absence of Staphylococcus epidermidis, a common causative pathogen in PJI, on the panel.
It’s Never Too Late to Re-Evaluate Your Syndromic Panel for Gastrointestinal Infections
First-hand experiences with an institutional strategy to reduce inappropriate ordering of syndromic gastrointestinal panels will be described. Recent changes to Medicare coverage of these panels and associated implications will also be discussed. Finally, the emerging opportunities for gastrointestinal illness testing will be reviewed.
Refreshment Break in the Exhibit Hall with Poster Viewing3:20 pm
How Many Contacts Can You Make in 30 Minutes? IN-PERSON ONLY
Bring yourself, your business or e-cards, and be prepared to share and summarize the key elements of your work in a short, two-minute sound bite. This session will be located in the exhibit hall and will be moderated.
Know Your Panel: Benefits and Risks of Multiplex Molecular Testing for the Diagnosis of Central Nervous System Infections
Use of multiplex panels for the diagnosis of central nervous system (CNS) infections offers comprehensive pathogen detection using minimal sample volume with a rapid turnaround time. Despite clear benefits over traditional testing, the shortcomings of multiplex testing include increased cost, concerning reports of false positive/negative results, and challenges to appropriate implementation. This presentation will address the benefits and limitations of using multiplex molecular panels for the diagnosis of CNS infections.
POINT/COUNTERPOINT DEBATE: Why Has Transition to Point-of-Care Testing Stalled Out?
Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children’s Hospital Los Angeles; Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California
- This panel will explore if the explosion of at-home SARS-CoV-2 testing that occurred during the SARS-CoV-2 pandemic will expand now that the public health emergency has been allowed to expire.
- This panel will discuss the technologies for point-of-care testing and which technologies are likely to prevail.
- This panel will explore what a future point-of-care and at-home test menu may look like.
Sample collection and preservation, without any doubt, are the most critical prerequisites for accurate test results for a final clinical diagnosis. Unfortunately, this process is dependent on human intervention that cannot be fully standardized or controlled. In this symposium, we discuss the need for correct and innovative sample collection and preservation for the diagnostics laboratories, introducing challenges and opportunities for current and future sample collection, preservation, and management.
Close of Day5:30 pm
Recommended Dinner Short Course6:00 pm
SC1: PAMA Reform: Reimbursement Challenges and Pathways Forward
*Separate registration required. See short courses page for details.
Registration Open7:15 am
Interactive Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Discussions page on the conference website for a complete listing of topics and descriptions.
- EUA to 510(k) transition
- OTC test requirements
- Multiplex assays
- IVD clinical study designs
- Overlapping regulatory strategy with the business case
Saliva as a Sample Type for the Detection and Surveillance of Respiratory Pathogens
- Evidence in the literature supporting saliva as a reliable sample type for the detection of respiratory pathogens
- Key considerations for working with this non-traditional sample type
- Insights gained from the COVID-19 response: self-collection, sample stability, simplified testing methods
- Reasons to incorporate saliva into your laboratory or surveillance systems, particularly in low-resource settings
VIRUSES: CNS - DIAGNOSIS AND SIGNIFICANCE
ウイルス：CNS - 診断と重要性
Viral CNS Disease Diagnostic Approaches
Central nervous system infections are a medical emergency requiring prompt diagnosis and treatment. Molecular methods are considered the gold standard for the diagnosis of viral CNS diseases; however, currently available tests are limited to a few most common viral pathogens. In this talk, the current state of diagnostics for viral CNS disease will be described and current gaps reviewed and discussed.
cfDNA and CNS Diagnostics
Pathogen cell-free nucleic acid exists in both plasma and CSF, allowing for the diagnosis of CNS infections via a variety of modalities. This talk will cover updates in cell-free nucleic acid detection of CNS infections.
Sponsored Presentation (Opportunity Available)9:30 am
Coffee Break in the Exhibit Hall. Last Chance for Poster Viewing.10:00 am
EV-D68 and the Utility of Immunologic Surveillance in Pandemic Preparedness
Despite advancements in the field of infectious diseases, current countermeasures against emerging pathogens, such as enterovirus D68, a virus associated with acute flaccid myelitis, are still limited. The use of immunologic and pathogen surveillance can provide information about the immunity and susceptibility of a population to infections. This in turn could help facilitate more rapid development of preventative tools and therapeutics against emerging infectious diseases of pandemic potential.
Herpesviridae and the CNS: Detection across Clinical Presentations
Herpesviruses can cause a range of central nervous system infections in both immunocompetent and immunocompromised hosts. Diagnostic strategies to accurately detect and interpret contribution to neurological disease can be challenging. Pathways to detect Herpes simplex viruses (HSV-1 and HSV-2) as well as Cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) will be discussed.
Sponsored Presentation (Opportunity Available)12:00 pm
Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own12:30 pm
Session Break1:30 pm
Networking Refreshment Break1:40 pm
APPLYING AI TO URINE TESTING
AI for Sepsis
Ramy Arnaout, MD, DPhil, FCAP, FASCP Associate Director, Clinical Microbiology Laboratories; Associate Professor, Department of Pathology Faculty, Division of Clinical Informatics, Department of Medicine, Beth Israel Deaconess Medical Center Faculty, Department of Systems Biology, Harvard Medical School
Ur-ine for Confusion: Have Molecular Diagnostic Tests for Uropathogens Gone Too Far?
Several commercial molecular tests designed to diagnose urinary tract infections have been recently made available to healthcare providers. In this presentation, we will provide a general overview of these tests, including a discussion of their proposed use, potential, and perils. We will also review how current regulatory requirements pertain to these tests and discuss what is needed to responsibly implement this technology.
The Challenge of Bringing the Science of AI to the Art of Culture Interpretation
Due to advancements in clinical microbiology laboratory automation, artificial intelligence (AI) and image analysis tools are emerging as an important tool in clinical microbiology culture diagnostics. With the convergence of these technologies, laboratories are enabled to use AI to support interpretation of bacterial cultures. However, with the power of AI comes the challenge of translating the nuances of culture interpretation into discrete points for use in image analysis software. This presentation will discuss various uses of AI for bacterial cultures and the challenges in developing algorithms and decision support tools for complicated microbiological cultures.
Artificial Intelligence in Urinary Tract Infection Diagnostics
Urinary tract infections are commonly overdiagnosed, yielding overtreatment and potentially delaying the correct diagnosis and treatment. The use of artificial intelligence shows promise in aiding the laboratory and providers in accurately identifying urinary tract infections.
Close of Summit4:35 pm